专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016059587A1 STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION 审中-公开
标题翻译：药物活性剂的稳定注射组合物及其制备方法
公开(公告)号：WO2016059587A1
公开(公告)日：2016-04-21
申请号：PCT/IB2015057920
申请日：2015-10-15
申请人： PIRAMAL ENTPR LTD
发明人： SONAVARIA VANDANA , UPADHYAY KAMAL KUMAR
IPC分类号： A61K38/12 , A61K9/08 , A61K31/675 , A61K38/49 , A61P31/00 , A61P35/00
CPC分类号： A61K38/49 , A61K9/0019 , A61K9/08 , A61K31/522 , A61K31/65 , A61K31/675 , A61K31/69 , A61K38/09 , A61K38/12 , A61K38/166 , A61K38/22 , A61K38/2257 , A61K45/06 , A61K47/10 , A61K47/26 , C12Y304/21073 , A61K2300/00
摘要： The present invention relates to a stable, non-aqueous and ready-to-use injectable composition of a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. The present invention also relates to a process for the preparation of the stable, non-aqueous and ready-to-use injectable composition of pharmaceutically active agent involving use of a non-solvent solvent system suitable for preparing a stabilized injectable composition comprising a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. It is not required to reconstitute the injectable composition of pharmaceutically active agent with water prior to administration, thereby rendering it an easy-to-use injectable composition.
摘要翻译：本发明涉及药物活性剂，药物活性剂或其药学上可接受的盐或其共晶体的稳定的，非水性的和即时可用的可注射组合物。本发明还涉及用于制备药物活性剂的稳定的，非水性的和即时可用的可注射组合物的方法，涉及使用适合于制备稳定的可注射组合物的非溶剂溶剂体系，所述稳定的可注射组合物包含药学活性剂药剂，药物活性剂或其药学上可接受的盐或共晶体。在给药之前不需要用水重构药物活性剂的可注射组合物，由此使其成为易于使用的可注射组合物。

2. 发明申请

WO2014009808A2 LIPIDATED PEPTIDES AS ANTI-OBESITY AGENTS 审中-公开
标题翻译：脂化肽作为抗肥胖药物
公开(公告)号：WO2014009808A2
公开(公告)日：2014-01-16
申请号：PCT/IB2013001837
申请日：2013-07-11
申请人： USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR V V I
发明人： MALETINSKA LENKA , ZELEZNA BLANKA , BLECHOVA MIROSLAVA , SPOLCOVA ANDREA
IPC分类号： C07K14/435
CPC分类号： A61K38/2257 , A61K47/543 , C07K14/575
摘要： Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.
摘要翻译：两种形式的催乳素释放肽PrRP31和PrRP20的脂质化的肽类似物代表食欲减退的化合物，其在外周给药后降低脑中的食物摄取和功能。通过肉豆蔻酸或棕榈酸在N-末端脂化的类似物PrRP31和PrRP20以高亲和力与大鼠垂体细胞系RC-4B / C和具有转染的人受体的CHO细胞系中的内源性受体GPR10结合。这些脂化肽也以剂量依赖性方式显着降低了禁食小鼠的食物摄取并且在与中心施用的天然PrRP31相当的剂量下具有相似的作用，但是这些作用更强且持续时间更长。有效的减食欲神经肽PrRP的脂质化在外周给药后诱导中枢作用，并因此使得PrRP的脂化类似物成为有希望的抗肥胖药物。

3. 发明申请

WO2008074865A1 DIMERIC PROLACTIN RECEPTOR LIGANDS 审中-公开
标题翻译：二聚体抑制素受体配体
公开(公告)号：WO2008074865A1
公开(公告)日：2008-06-26
申请号：PCT/EP2007/064329
申请日：2007-12-20
申请人： NOVO NORDISK A/S , CHRISTENSEN, Leif , NØRSKOV-LAURITSEN, Leif , RISEGAARD, Lone , BILLESTRUP, Nils , TARABYKINA, Svetlana
发明人： CHRISTENSEN, Leif , NØRSKOV-LAURITSEN, Leif , RISEGAARD, Lone , BILLESTRUP, Nils , TARABYKINA, Svetlana
IPC分类号： A61K38/22 , A61K47/22 , A61P35/00
CPC分类号： A61K38/2257 , A61K38/27 , A61K2300/00
摘要： The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.
摘要翻译：该专利申请涉及催乳素分子的拮抗二聚体及其在治疗癌症中的用途。

4. 发明申请

WO2005094854A1 MODIFIED NUTRACEUTICAL COMPOSITION 审中-公开
标题翻译：改良的营养成分
公开(公告)号：WO2005094854A1
公开(公告)日：2005-10-13
申请号：PCT/AU2005/000459
申请日：2005-03-30
申请人： TORBANGUN PTY LTD , WAHLQVIST, Mark, Lawrence , WATTANAPENPAIBOON, Naiyana , DAMANIK, Muhammad, Rizal, Martua
发明人： WAHLQVIST, Mark, Lawrence , WATTANAPENPAIBOON, Naiyana , DAMANIK, Muhammad, Rizal, Martua
IPC分类号： A61K35/78
CPC分类号： A61K36/53 , A23L33/11 , A23L33/12 , A61K31/53 , A61K38/2257 , A61K45/06 , A61K2300/00
摘要： A nutraceutical composition for the treatment of lactating females, including humans, including a lactagogue component derived from, or present in the Coleus amboinicus plant, or an isolate therefrom or fraction thereof; and optionally a nutraceutically acceptable carrier therefor.
摘要翻译：一种用于治疗包括人在内的哺乳期雌性的营养食品组合物，包括源自或存在于金丝桃属植物中的哺乳动物成分，或其分离物或其部分; 和任选的营养可接受的载体。

5. 发明申请

WO2005077404A1 USE OF LUTEINIZING HORMONE (LH) AND CHORIONIC GONADOTROPIN (HCG) FOR PROLIFERATION OF NEURAL STEM CELLS AND NEUROGENESIS 审中-公开
标题翻译：用于促进神经干细胞和神经细胞增殖的促黄体激素（LH）和氯膦酸（HCG）的使用
公开(公告)号：WO2005077404A1
公开(公告)日：2005-08-25
申请号：PCT/CA2005/000184
申请日：2005-02-14
申请人： STEM CELL THERAPEUTICS CORP. , WEISS, Samuel , ENWERE, Emeka , ANDERSEN, Linda , GREGG, Christopher
发明人： WEISS, Samuel , ENWERE, Emeka , ANDERSEN, Linda , GREGG, Christopher
IPC分类号： A61K38/24
CPC分类号： A61K35/30 , A61K35/12 , A61K38/2257 , A61K38/24 , C12N5/0623 , C12N2501/11 , C12N2501/14 , C12N2501/31 , C12N2501/315 , A61K2300/00
摘要： The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
摘要翻译：本发明提供了使用信息素，促黄体激素（LH）和/或人绒毛膜促性腺激素（hCG）增加神经干细胞数量或神经发生的方法。该方法可以在体内实施以获得更多的原位神经干细胞，其又可产生更多的神经元或神经胶质细胞以补偿丢失或功能失调的神经细胞。该方法也可以在体外实施以在培养物中产生大量的神经干细胞。培养的干细胞可用于例如患有或怀疑具有神经变性疾病或病症的患者或动物的移植治疗。

6. 发明申请

WO2003012043A2 ENHANCING ORGAN MATURITY IN NEONATES AND PREDICTING THEIR DURATION OF INTENSIVE CARE 审中-公开
标题翻译：增强有机成分，预测其强化护理时间
公开(公告)号：WO2003012043A2
公开(公告)日：2003-02-13
申请号：PCT/US2002/023983
申请日：2002-07-26
申请人： HANAUSKE-ABEL, Hartmut, M. , HANAUSKE, Axel-Rainer
发明人： HANAUSKE-ABEL, Hartmut, M. , HANAUSKE, Axel-Rainer
IPC分类号： C12N
CPC分类号： A61K31/27 , A61K38/2257 , A61K38/27 , A61K38/30 , A61K38/39 , G01N33/6887 , G01N33/6893 , G01N2333/78
摘要： The present invention is directed to methods of enhancing organ maturity of premature human neonates or increasing collagen type IV formation in a living system by administering a growth factor, a gene encoding a growth factor, or an agent that increases growth factor formation to the living system under conditions effective to increase collagen type IV formation. Another aspect of the present invention relates to a method of predicting a premature human neonate's length of stay in a neonatal intensive care unit as well as the anticipated medical costs incurred during said stay by providing a sample from the premature human neonate and determining biomarkers derived from the extracellular matrix in the sample. The biomarker levels or ratios thereof in the sample are compared to a standard to ascertain the premature human neonate's length of stay in a neonatal intensive care unit as well as the anticipated medical costs incurred during said stay.
摘要翻译：本发明涉及通过施用生长因子，编码生长因子的基因或将生长因子形成增加至生物体的药剂来增加早产新生儿的器官成熟或增加生物体系中的胶原IV型形成的方法在有效增加胶原IV型形成的条件下。本发明的另一方面涉及一种预测新生儿早产新生儿在新生儿重症监护病房中的停留时间的方法，以及通过提供来自早产的人新生儿的样品和确定来自样品中的细胞外基质。将样品中的生物标志物水平或比例与标准进行比较，以确定新生儿重症监护室中过早的新生儿停留时间以及在所述停留期间发生的预期医疗费用。

7. 发明申请

WO00038704A1 USE OF PEPTIDE 审中-公开
标题翻译：使用肽
公开(公告)号：WO00038704A1
公开(公告)日：2000-07-06
申请号：PCT/JP1999/007199
申请日：1999-12-22
IPC分类号： C12N15/09 , A61K31/00 , A61K38/00 , A61K38/17 , A61P15/00 , C07K14/47
CPC分类号： A61K38/2257
摘要： Use of a polypeptide recognized as a ligand by a G protein-coupled receptor protein. Because of having an effect of promoting the secretion of oxytocin, this ligand polypeptide is useful as drugs for ameliorating, preventing and treating various diseases relating to the oxytocin secretion such as week pains, atonic bleeding, before or after explusion of placenta, uterine recovery failure, etc.
摘要翻译：使用被G蛋白偶联受体蛋白识别为配体的多肽。由于具有促进催产素分泌的作用，该配体多肽可用作改善，预防和治疗与催产素分泌有关的各种疾病的药物，例如周痛，无症状出血，胎盘剥离前后，子宫恢复失败等等

8. 发明申请

WO1999058097A2 USE OF ANTI-PROLACTIN AGENTS TO TREAT PROLIFERATIVE CONDITIONS 审中-公开
标题翻译：使用抗精神病药物治疗增殖性疾病
公开(公告)号：WO1999058097A2
公开(公告)日：1999-11-18
申请号：PCT/US1999010545
申请日：1999-05-12
申请人： GREENVILLE HOSPITAL SYSTEM , CHEN, Wen, Y. , WAGNER, Thomas, E.
发明人： GREENVILLE HOSPITAL SYSTEM
IPC分类号： A61K00/00
CPC分类号： C07K14/72 , A61K38/2257 , A61K2300/00
摘要： The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.
摘要翻译：本发明涉及在催乳素受体中作为拮抗剂的人催乳素的变体形式，以及这些变体在治疗人类癌症和增殖性疾病（包括乳腺和前列腺的良性和恶性疾病）中的应用。

9. 发明申请

WO1993001802A1 COMPOSITION FOR THE SUSTAINED AND CONTROLLED RELEASE OF A MEDICINAL PEPTIDE-CONTAINING SUBSTANCE, AND PREPARATION METHOD THEREFOR 审中-公开
标题翻译：用于含有药物含肽物质的持续和控制释放的组合物及其制备方法
公开(公告)号：WO1993001802A1
公开(公告)日：1993-02-04
申请号：PCT/CH1992000146
申请日：1992-07-15
申请人： DEBIO RECHERCHE PHARMACEUTIQUE S.A.
发明人： DEBIO RECHERCHE PHARMACEUTIQUE S.A. , HEIMGARTNER, Frédéric , ORSOLINI, Piero
IPC分类号： A61K09/16
CPC分类号： A61K38/25 , A61K9/1647 , A61K9/1694 , A61K38/09 , A61K38/1808 , A61K38/21 , A61K38/2242 , A61K38/2257 , A61K38/23 , A61K38/26 , A61K38/28 , A61K38/31 , A61K38/33 , C07K7/23
摘要： A composition for the sustained and controlled delivery of a medicinal peptide-containing substance having formula (I): Ac-D-Nal-D-pClPhe-R3-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH¿2?, in which R?3¿ is D-Pal or D-Top, is prepared. The composition is supplied in the form of microspheres made of a biodegradable polymer material incorporating a water-insoluble salt of said peptide of formula (I).

10. 发明申请

WO2011097149A3 TAXANE-AND TAXOID-PROTEIN COMPOSITIONS 审中-公开
标题翻译：紫杉醇和紫杉醇 - 蛋白质组合物
公开(公告)号：WO2011097149A3
公开(公告)日：2012-03-22
申请号：PCT/US2011023112
申请日：2011-01-31
申请人： ONCBIOMUNE L L C , HEAD JONATHAN F , ELLIOTT ROBERT L
发明人： HEAD JONATHAN F , ELLIOTT ROBERT L
IPC分类号： A61K9/00 , A61K31/337 , A61K47/42 , A61K47/44 , A61K47/48
CPC分类号： A61K31/337 , A61K9/0019 , A61K38/1808 , A61K38/2257 , A61K38/38 , A61K38/40 , A61K45/06 , A61K47/42 , A61K47/44 , A61K47/48284 , A61K47/483 , A61K47/643 , A61K47/644 , A61K2300/00
摘要： Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.
摘要翻译：可以通过将蛋白质水溶液与含有紫杉烷或紫杉烷的第二溶液组合而制备包含紫杉烷或紫杉烷类如紫杉醇的组合物和蛋白质如白蛋白或金属 - 转铁蛋白如镓 - 转铁蛋白，非离子表面活性剂和醇; 将组合溶液的pH调节至约7.9至约8.3; 并纯化pH调节的溶液以除去分子量小于10,000Da的溶质。可以制备基本上不含非离子表面活性剂如Cremophor EL的这样的组合物，并且可用于治疗诸如乳腺癌的癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式